期刊文献+

盐酸特拉唑嗪与PKRP联合治疗前列腺增生合并高血压的临床研究 被引量:3

下载PDF
导出
摘要 目的评价盐酸特拉唑嗪与经尿道前列腺等离子双极电切术(PKRP)联合治疗前列腺增生(BPH)合并高血压患者的有效性、安全性及依从性。方法研究对象为临床型BPH合并高血压患者,均接受PKRP术、睡前口服盐酸特拉唑嗪1~6mg,随访3个月。评价指标:国际前列腺症状评分(IPSS)、收缩压、舒张压、最大尿流率(Q max),同时对不良事件进行分析。结果 IPSS从基线的21.55±4.82降至4周末的15.44±3.66和3月末的12.96±3.11(P<0.01),Qmax从基线的(7.63±4.41)mL/s提高至4周末的(12.55±1.34)mL/s和3月末的(15.51±2.92)mL/s(P<0.01),收缩压从基线的(161.00±12.33)mmHg降至4周末的(148.79±7.27)mmHg和3月末的(132.29±6.13)mmHg(P<0.01),舒张压从基线的(102.28±4.99)mmHg降至4周末的(95.98±4.61)mmHg和3月末的(81.09±4.26)mmHg(P<0.01)。结论采用盐酸特拉唑嗪与PKRP联合治疗前列腺增生合并高血压,不仅能有效改善患者下尿路梗阻症状,提高生活质量,有效控制血压,同时可提高患者的安全性和依从性。
出处 《现代泌尿外科杂志》 CAS 2012年第3期303-305,共3页 Journal of Modern Urology
  • 相关文献

参考文献11

  • 1MARUENDA J,BHATNAGAR V.Lowenthal DT1 Hypertension in the elderly with coexisting benign p rostatic hyperp lasia1[J].Urology,1999,53 (Suppl 3A):72131.
  • 2MICHEL MC,HEEMANN U,SCHUMACHER H,et al.1Association ofhypertension with symp toms of benign p rostatic hyperplasia1[J].J Urol,2004,172:1390-1393.
  • 3郭利君,张祥华,李培军,那彦群.高血压对良性前列腺增生组织中血管新生影响的研究[J].中华医学杂志,2005,85(9):606-609. 被引量:30
  • 4PAREEK G,SHEVCHUK M,ARMENAKAS NA,et al.The effect offinasteride on the exp ression of vascular endothelial growth factor and microvessel density:a possible mechanism for decreased prostaticbleeding in treated patients1[J].J Urol,2003,169:202231.
  • 5KOBAYASHI S,TANG R,SHAPIRO E,et al.Characterization localization of prostatic alphal aderenoceptors using radio ligand binding on slide-mounted tissue section[J].J Urol,1993,150 (6),2002-2006.
  • 6CHEOL KWAK,JEONG KI LEE,AND JA HYEON KU.High-dose terazosin therapy (5 mg) in korean patients with lower urinary tract symptoms with or without concomitant hypertension:A prospective,open-label study[J].J Yonsei Med J,2007,31,48(6):994-1000.
  • 7杜广辉,齐隽,宋健,丁强,王行环,孔垂泽,靳风烁,蔡松良,张炜,叶章群,那彦群.盐酸特拉唑嗪治疗中国人群良性前列腺增生患者的多中心临床研究[J].中华泌尿外科杂志,2010,31(5):343-346. 被引量:17
  • 8TURKERI LN,OXYUREK M,ERSEV D,et al.Apoptotic regression of prostatic tissue induced by short-term doxazosin treatment in benign prostatic hyperplasia[J].Arch Esprol,2001,54:191-196.
  • 9GLASSMAN DT,CHON JK,BORKOWSKI A,et al.Combined effect of terazpsinand finasteride on apoptisis,cell proliferation and transforming growth factor-B expression in benign prostatic hyperplasia[J].The Prostate,2001,46:45-51.
  • 10LEPOR H,JONES K,WILLIFORD W.The mechanism of adverse events associated with terazosin:an analysis of the Veterans Affairs cooperative study[J].J Urol,2001,58(4):508-516.

二级参考文献19

  • 1郭利君,张祥华,李培军,那彦群.良性前列腺增生与原发性高血压的相关性研究[J].中华外科杂志,2005,43(2):108-111. 被引量:59
  • 2Kirby RS.The natural history of benign prostatic hyperplasia:what have we learned in the last decade? Urology,2000,56(5Suppl 1):3-6.
  • 3Girman CJ.Population based studies of the epidemiology of benign prostatic hyperplasia.Br J Urol,1998,82(Suppl 1):34-43.
  • 4Gjertson CK,Walmsley K,Kaplan SA.Benign prostatic hyperplasia:now we can begin to tailor treatment.Cleve Clin J Med,2004,71:857-865.
  • 5Lepor H.Alpha blockers for the treatment of benign prostatic hyperplasia.Rev Urol,2007,9:181-190.
  • 6O' Leafy MP.Treatment and pharmacologic management of BPH in the context of common comorbidities.Am J Manag Care,2006,12(5 Suppl):129-140.
  • 7Tanaka Y,Masumori N,Itoh N,et al.Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia.J Urol,2002,167:2492-2495.
  • 8Roehrborn CG,Oesterling JE,Auerbach S,et al.The Hytrin Community Assessment Trial Study:a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostactic hyperplasia.Urology,1996,47:159-168.
  • 9Weidner N, Carroll PR, Flax J, et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol,1993,143∶401-409.
  • 10Kwak C,Jin R.J, Lee C,et al.Thrombospondin-1,vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia. BJU,2002,89:303-309.

共引文献46

同被引文献21

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部